All filters
Abstracts
K156N integrase substitution in combination with 3’PPT resistance mutations against dolutegravir
R. Gruters
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Long-term Efficacy, Safety, and Durability of Ibalizumab-based Regimens in Subgroup of TMB- 202 Participants
H. Jullien
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Residual HIV-1 RNA in 4d on/3d off (ANRS 170 QUATUOR) through W96
S. Lambert
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Switch to ART with BIC/FTC/TAF achieves virological control in patients with low level viremia
I. Santos
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Implementation of HCV- infection treatment programm with DAA in armenia among HIV- infected patients in COVID-19 era
N. Sargsyants
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Impacts of Differentiated Service Delivery Model (DSDM) on Adherence (ADH) to clinical appointment Among Children and Adolescent Living with HIV (CALHIV) attending at Mbeya Center of Excellence (COE), Baylor-Tanzania
E. Mgeyi
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
HIV and SARS-CoV-2: the interplay of two wicked problems
A. Vandamme
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Eu HIV & Hep Abstracts 2022_56
L. Ramirez
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Prevalence and viral load suppression rate among children and adolescents with dual infections (any two of HIV, HBV, and HCV) in Nnewi, Nigeria
S. Kalu
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Proviral DNA for detection of HIV-1 subtype A drug resistance mutations
D. Turner
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Combined COVID-19 vaccination and hepatitis C virus screening intervention for high-risk populations at a centre for addiction services in Barcelona, Spain
J. Lazarus
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Combined COVID-19 vaccination and hepatitis C virus and HIV screening intervention for high- risk populations at a mobile testing unit in Madrid, Spain
J. Lazarus
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Community perspectives on self- testing for HIV and HCV in the WHO European region
S. North
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Viral load suppression after three-year Ibalizumab treatment in a multidrug-resistant HIV-1- infected woman: Clinical experience.
I. Santos
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
CASE - HIV+ End-Stage Renal Disease Patient with Immunosuppressive Drug-Drug Interactions Received Successful Transplantation after Ibalizumab Suppressed Switch
S. Sharma
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Clinical course of AIDS with COVID-19 coinfection with prolonged SARS CoV-2 replication despite remdesivir/molnupiravir treatment.
B. Aksak-Wąs
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
A Case of IRIS Syphilis Due to Prozone Effect
Y. Rahman
Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Persistence on F/TAF versus F/TDF for HIV Pre-Exposure Prophylaxis: A Real-World Evidence Analysis in the United States
C. Cruz-Beniasians
Reviews in Antiviral Therapy & Infectious Diseases 11, 2021
Presented at:
HIV Prevention Summit 2021
Abstracts
Community PrEP Service delivery for Female Sex Workers in Ghana
G. Lundby Sorensen
Reviews in Antiviral Therapy & Infectious Diseases 11, 2021
Presented at:
HIV Prevention Summit 2021
Abstracts
Socio-demographics of individuals initiated on HIV pre-exposure prophylaxis (PrEP) in Nigeria
A. Idemudia
Reviews in Antiviral Therapy & Infectious Diseases 11, 2021
Presented at:
HIV Prevention Summit 2021
Abstracts
Uptake of HIV post-exposure prophylaxis, completion rates and self-reported reasons for non-completion among health care workers at Mbarara Regional Referral Hospital
D. Muzoora Musiime
Reviews in Antiviral Therapy & Infectious Diseases 11, 2021
Presented at:
HIV Prevention Summit 2021
Abstracts
Characterizing Non-Occupational Post Exposure Prophylaxis for HIV in 5 Urban Health Centers of Kampala, Uganda: January 2016 - June 2019
L. Mills
Reviews in Antiviral Therapy & Infectious Diseases 11, 2021
Presented at:
HIV Prevention Summit 2021
Abstracts
Intimate partner violence and gender-based violence among people living with HIV in southern Nigeria
C. Okafor
Reviews in Antiviral Therapy & Infectious Diseases 11, 2021
Presented at:
HIV Prevention Summit 2021
Abstracts
Post-Exposure Prophylaxis, Post-Violence Care and Ongoing HIV Risk: Missed Opportunities for HIV Prevention through Pre-Exposure Prophylaxis and Other Interventions
L. Mills
Reviews in Antiviral Therapy & Infectious Diseases 11, 2021
Presented at:
HIV Prevention Summit 2021